Wall Street analysts’ outlook for ATAI Life Sciences N.V (ATAI)

With 1.91 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.65 million shares. The 52-week range on ATAI shows that it touched its highest point at $2.85 and its lowest point at $1.03 during that stretch. It currently has a 1-year price target of $7.40. Beta for the stock currently stands at 1.18.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ATAI was down-trending over the past week, with a drop of -16.91%, but this was up by 8.86% over a month. Three-month performance surged to 8.18% while six-month performance rose 33.33%. The stock lost -6.01% in the past year, while it has gained 29.32% so far this year. A look at the trailing 12-month EPS for ATAI yields -0.80 with Next year EPS estimates of -0.61. For the next quarter, that number is -0.14. This implies an EPS growth rate of -216.57% for this year and 22.56% for next year.

Float and Shares Shorts:

At present, 167.82 million ATAI shares are outstanding with a float of 124.98 million shares on hand for trading.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ATAI since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.6167 being high and -$0.88393 being low. For ATAI, this leads to a yearly average estimate of -$0.79143.